First indigenous antibiotic drug named Nafithromycin for resistant infections launched by Dr. Jitendra Singh.
On November 20, Union Minister Dr Jitendra Singh formally launched ” Nafithromycin”, the first indigenous antibiotic for resistant infections, a significant step for India’s biotechnology sector.
He said the three-day treatment with Nafithromycin is a revolutionary step against drug-resistant pneumonia, which is responsible for over two million deaths annually worldwide.
The antibiotic “Nafithromycin” has been developed in collaboration with the “Biotechnology Industry Research Assistance Council” (BIRAC), a unit of the Department of Biotechnology.
It has been launched in the market by the pharma company “Wolkardt” under the brand name “Miqnaf”.
It is the country’s first indigenously developed antibiotic aimed at tackling antimicrobial resistance (AMR).
This innovation is designed for the treatment of community-acquired bacterial pneumonia (CABP), a serious disease caused by drug-resistant bacteria.
It disproportionately affects vulnerable populations, including children and the elderly, as well as immune-compromised hosts such as patients with diabetes, cancer, etc.
